Previous 10 | Next 10 |
SCYNEXIS (SCYX): Q3 GAAP EPS of -$0.28.Cash and cash equivalents of $29.5M.Press Release For further details see: SCYNEXIS reports Q3 results
In October , SCYNEXIS submitted a New Drug Application ( NDA ) for ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC) with expected approval in mid-2021 . SCYNEXIS estimates that there are over 15 million antifungal ...
JERSEY CITY, N.J., Oct. 21, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it is presenting three posters on its late-stage, n...
Scynexis (SCYX) has submitted a New Drug Application ((NDA)) to the FDA for oral ibrexafungerp for the treatment of vulvovaginal candidiasis ((VVC)), also known as vaginal yeast infection. The Company expects to receive notification if the NDA has been accepted for filing and substantive revi...
NDA s ubmission is supported by positive data from two Phase 3 studies ( VANISH Program ) in women with vulvovaginal candidiasis (VVC) As a qualified infectious disease product (QIDP) , ibrexafungerp is ...
JERSEY CITY, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of two posters at the Nurse Practitione...
The following healthcare companies have filed for mixed shelf offerings: More news on: Citius Pharmaceuticals, Inc., Flexion Therapeutics, Inc., SCYNEXIS, Inc., Healthcare stocks news, , Read more ...
JERSEY CITY, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Dr. Marco Taglietti, Chief Executive Officer, will part...
Two oral presentations by VVC experts on ibrexafungerp, one in-vitro activity study and one on VANISH-303 study SCYNEXIS to sponsor symposium: “Current Challenges and Advancements in the Treatment of Vulvovaginal Candidiasis” JERSEY CITY, N.J., Aug. 13, 2020 ...
In July, SCYNEXIS announced that it had successfully conducted pre-NDA meetings with the FDA regarding ibrexafungerp for the treatment of Vulvovaginal Candidiasis (VVC) more commonly known as vaginal yeast infection. NDA submission for this indication remains on track for Q4 2020. I...
News, Short Squeeze, Breakout and More Instantly...
JERSEY CITY, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will receive a $10 million development milestone payment un...